7th January 2013

Dear Sir/Madam

CONSULTATION DOCUMENT: ARM 83 PIRINASE HAYFEVER RELIEF FOR ADULTS 0.05% NASAL SPRAY

REQUEST TO RECLASSIFY A PRODUCT FROM P TO GSL

I am writing to inform you that consultation document ARM 83 which includes the applicant’s Reclassification Summary and Patient Information Leaflet, has been posted on the MHRA website today (www.mhra.gov.uk). The consultation seeks your views on the reclassification from P to GSL of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray (fluticasone propionate).

You are invited to comment on the proposal, a copy of which is attached. A form for your reply is also attached.

Comments should be sent to me either by post to room 3-M, 151 Buckingham Palace Road, London SW1W 9SZ or by email (reclassification@mhra.gsi.gov.uk) to arrive by 1st February 2013. Contributions received after that date cannot be included in the exercise.

To help informed debate on the issues raised by this consultation exercise, and within the terms of the Freedom of Information Act, the Agency intends to make copies of comments received publicly available. Unless you state otherwise we will assume that you have no objections to your comments being publicly available on the Agency’s website.

Yours faithfully

Abiodun Aderogba
Reclassification Unit
To: Abiodun Aderogba
From: ____________________

MHRA
Room 3-M
151 Buckingham Palace Road
LONDON SW1W 9SZ

ALL RESPONDENTS MUST TICK ONE OF THE FOLLOWING BOXES

• My reply may be made freely available
• I wish parts of my reply to remain confidential*
• I wish my reply to remain confidential*

*Please use the space below to explain why you feel the information in your reply should be treated as confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete

Explanation regarding why your response should remain confidential

_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________

Name: ___________________________ Signature

Date:
RECLASSIFICATION SUMMARY FOR P TO GSL APPLICATION

PIRINASE HAYFEVER RELIEF FOR ADULTS 0.05% NASAL SPRAY
(FLUTICASONE PROPIONATE)

An application for a change in legal classification from P to GSL for fluticasone propionate aqueous nasal spray, 50 micrograms per spray for the treatment of seasonal allergic rhinitis (hay fever) in adults aged 18 years and over.

1. Applicant details

Name of the applicant: GlaxoSmithKline Consumer Healthcare

2. Product Details

Existing Product Name and MA number:
Pirinase Hayfever 0.05% Nasal Spray PL 00079/0616

Proposed Product Name and MA number:
Pirinase Hayfever Relief for Adults 0.05% Nasal Spray PL 00079/0688

Active ingredient:
Fluticasone Propionate 50 micrograms per actuation

Indications:
For the treatment of seasonal allergic rhinitis including hay fever.
This medicine also provides symptomatic relief of sneezing, itchy and runny nose, itchy and watery eyes, nasal congestion and associated sinus discomfort.

Current dosage including age-limits and restrictions on length of treatment:

Adults aged 18 years and over:
Two sprays into each nostril once a day, preferably in the morning. Once symptoms are under control a maintenance dose of one spray per nostril once a day may be used.
Total daily administration should not exceed 4 sprays (200 micrograms).

Elderly: The normal adult dosage is applicable.
Pirinase Hayfever Relief for Adults is not recommended for children or adolescents under 18 years of age.
For full therapeutic benefit, regular usage is recommended.
If symptoms have not improved after 7 days treatment, medical advice must be sought. The advice of a doctor or pharmacist should also be sought if symptoms have improved but are not adequately controlled.
The medicine should not be used continuously for more than one month without consulting a doctor.

**Pack Size**
60 metered sprays

3. **Rationale for the reclassification**

Allergic rhinitis is one of the most common conditions in the UK, with studies estimating that more than 30% of people experience the condition at some point in their life. Rhinitis has a significant impact on the sufferer’s quality of life and can affect the physical, psychological and social aspects of their lives.

Seasonal allergic rhinitis, commonly known as hay fever, affects up to one-in-five people at some time in their life. The associated symptoms of sneezing, runny or blocked nose and itchy or watery eyes occur in those people who are allergic to pollen. What may seem mild to a non-sufferer, the above symptoms cause significant morbidity particularly in terms of poor sleep and attendance/performance at school or work.

Pirinase Hayfever 0.05% Nasal Spray, containing fluticasone propionate (FP), 50 micrograms per spray, is currently available as a Pharmacy (P) medicine, and is recommended for use throughout the hay fever season to treat and prevent the common symptoms of allergic rhinitis. Pirinase Hayfever Relief for Adults 0.05% Nasal Spray will be the first General Sales List (GSL) product containing fluticasone propionate for the treatment of seasonal allergic rhinitis and the support for general sale availability is set out below.

3.1. **Hazard to Health**

Seasonal allergic rhinitis (hay fever) is established as a suitable indication for self diagnosis and treatment by products with GSL status.

The very extensive clinical experience with intranasal fluticasone propionate shows that the risks associated with its use are small.

The most commonly reported adverse events (AEs) are nasal symptoms associated with local irritation related to use of an aqueous spray formulation. These are usually mild and reversible. Hypersensitivity reactions have been reported very rarely. Systemic effects may occur with high dosage for prolonged periods, but this is unlikely when fluticasone propionate is used at the recommended dose and for a restricted period of time for the relief of hayfever symptoms. There are few clinically significant drug-drug interactions with appropriate advice provided in the Summary of Product Characteristics (SmPC) and in the patient information leaflet. Acute overdose does not present a risk.

The reclassification of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray to GSL status does not pose any additional safety concerns not already included in the SmPC and patient information leaflet. It is also relevant to note that Beconase Hayfever Relief for Adults has been available as a GSL product in the UK since 2003 with indications
(seasonal allergic rhinitis) and duration of use (1 month) similar to that proposed for Pirinase Hayfever Relief.

3.2. Risk of misuse

The risks associated with the misuse of Pirinase Hayfever Relief for Adults 0.05% Nasal Spray are discussed below.

- **Ability to self diagnose and treat seasonal allergic rhinitis:** Individuals can accurately self-diagnose and manage their condition. Symptoms are easily recognised and the scope for misdiagnosis is limited through the provision of further information about the condition in the patient information leaflet.

- **Ability to use the product correctly:** To help patients select the most appropriate product, the pack clearly states the age groups for which the product is intended. Both pack and leaflet provide clear dosage instructions and the recommended duration of use. The leaflet provides an illustrated guide on how to use the spray. The dose from the spray is metered and so administration of excess dose should not be a problem. In the case of patients experiencing side effects, the leaflet provides necessary information on what to do should they wish to seek further advice.

- **Prolonged or excessive use:** Both the pack and leaflet advise users to seek medical advice if symptoms have not improved after 7 days. Users are also advised not to use the product continuously for more than 1 month without seeking medical advice.

- **Use by children and adolescents:** Pirinase Hayfever Relief for Adults 0.05% Nasal Spray should only be used by adults aged 18 years old and over. This is clearly reflected on pack and in the leaflet provided.

- **Abuse:** There have been very few reported cases of abuse, or of symptoms suggestive of recreational use, such as euphoria and hallucinations. Given the estimated exposure of over 29 million patient years, the rarity of these reports supports the conclusion that abuse potential is negligible. It has a low potential for harm from inappropriate use, due to a combination of the inherent characteristics of the active ingredient and the dosage form and administration method of the product. Abuse potential is thereby not only demonstrably low but also very unlikely to pose harm to health, even in the unlikely event of misuse.

3.3. Special precautions in handling

There are no special precautions required. The only handling precaution is that the products should not be stored above 30°C.
3.4. Convenience to the purchaser

It will be more convenient to a purchaser to be able to buy a product from general retail stores than pharmacies. Not only are there more general retail stores than pharmacies, they also have longer opening hours.

Availability on general sale will enable patients to manage their hay fever immediately when it commences and provides a wider choice of medicinal products for the treatment of seasonal allergic rhinitis.

4. Support for the reclassification

This is a company application; there is no additional support from experts or organisations.

5. Specific GSL requirements

Some specific changes to the product information, reflected in the labelling and patient information leaflet, have been made in order to decrease the possibility of inappropriate use of the product.

- To amend the name of the product to ‘Pirinase Hayfever Relief for Adults 0.05% Nasal Spray’.
- To restrict the indications for the GSL product to “the treatment of seasonal allergic rhinitis including hay fever in adults aged 18 years and over”.
- To recommend the use of the product for a maximum of 7 days, after which time medical advice should be sought if symptoms have not improved.
- To include a warning that the product should not be used continuously for longer than 1 month without medical advice.
- Maximum daily dose will be restricted to two sprays per nostril for the GSL product (i.e. total daily dose up to 200 micrograms). The option to treat twice a day is restricted to the P product.
- Prevention of allergic rhinitis is restricted to the P product.
- The Patient Information Leaflet contains general and educational information about hay fever.

6. Safety Profile

The safety profile of intranasal FP is well-defined and supported by over 20 years of post-marketing experience, including ten years as a non-prescription product. The benefit/risk profile of intranasal FP for the treatment of seasonal allergic rhinitis continues to be favourable and the safety profile is reflected in the Reference Safety Information (RSI) included in GSK’s Global Data Sheet. The most commonly reported events are non-serious symptoms associated with local irritation related to the use of an aqueous spray formulation, including epistaxis, dryness and irritation of the nose and throat, and unpleasant taste/smell. Nasal septal perforation has also been reported very rarely following the use of intranasal corticosteroids. Hypersensitivity reactions (including anaphylaxis/anaphylactic reactions) have been reported very rarely. Intranasal FP had a bioavailability of less than 0.5% and caused no detectable
hypothalamo-pituitary-adrenal (HPA) axis suppression in 7 studies with intranasal doses ranging from 88 to 800 micrograms per day. Nevertheless, product labelling includes a warning that systemic effects of nasal corticosteroids may occur, particularly at higher than recommended doses, administered for prolonged periods. These effects are much less likely with intranasal FP to occur than with oral or inhaled corticosteroids and may vary in individual patients and between different corticosteroid preparations.

There are very clear benefits associated with the use of intranasal FP in the treatment of seasonal allergic rhinitis. Intranasal FP is more effective than non-sedating antihistamines in providing relief of nasal symptoms and as effective in relieving ocular symptoms. The available data have demonstrated the advantages of intranasal FP over antihistamines. The onset of action is rapid with relief on symptoms noted within 24 hours and intranasal FP is effective when used on an as needed basis.

In summary, Pirinase Hayfever Relief for Adults 0.05% Nasal Spray has a well established safety profile and post-marketing experience has shown that the wider public availability of the product through pharmacies has not significantly changed the safety profile of the product. Reclassification to GSL status can be appropriately managed through the additional labelling restrictions i.e. for use in adults only, limiting the duration of use to one month, and limiting the indication to seasonal allergic rhinitis in order to help ensure appropriate self selection for use.

Given the very extensive experience with Pirinase Hayfever Nasal Spray, there are adequate data to demonstrate that the product fulfils the criteria for GSL status.
Pirinase®
Hayfever Relief for Adults
0.05% Nasal Spray
Fluticasone Propionate

Please read right through this leaflet before you start using this medicine. This medicine is available without prescription, but you still need to use Pirinase Hayfever Relief for Adults 0.05% Nasal Spray carefully to get the best results from it.

- Keep this leaflet you may need to read it again.
- If you have any questions, or if there is anything you do not understand, ask your pharmacist.

In this leaflet:
1. What Pirinase Hayfever Relief does
2. Check before you use Pirinase Hayfever Relief
3. How to use Pirinase Hayfever Relief
4. Possible side effects
5. How to store Pirinase Hayfever Relief
6. Further information

1. What Pirinase Hayfever Relief does
Pirinase Hayfever Relief is used to treat the allergic symptoms of hayfever including sneezing, itchy and watery eyes and a runny, itchy or blocked nose, for up to 24 hours.

The active ingredient is fluticasone propionate, a corticosteroid which, when used every day, has an anti-inflammatory action and works in a similar way to natural body chemicals to control inflammation. This spray helps to control your body’s reactions to allergens (pollen) in the environment.

2. Check before you use Pirinase Hayfever Relief
Do not use Pirinase Hayfever Relief:

- if you have ever had an allergic reaction to Fluticasone propionate or to any of the other ingredients (listed in Section 4).
- if you are under 18 years.

Take special care with Pirinase Hayfever Relief

• Talk to your doctor or pharmacist before using Pirinase Hayfever Relief if you have an infection in your nose or sinuses or you have recently had surgery, an injury or ulcers in your nose.
• If your symptoms do not improve, or are not well controlled, after 7 days, talk to your doctor or pharmacist.
• Do not use continuously for more than 1 month unless your doctor tells you to.

If you are taking other medicines
Talk to your doctor or pharmacist before using this medicine if you are taking any prescribed medicines, particularly corticosteroid medicines (including cream, ointment, nasal sprays, inhalers, eye drops, and injections). Do not use with olopatadine (an anti-H1 medicine) or ketoconazole (for fungal infections).

Pregnancy and breast feeding
Talk to your doctor before using Pirinase Hayfever Relief if you are pregnant, trying to become pregnant or are breast feeding.

3. How to use Pirinase Hayfever Relief
Always shake well before use. Only use in the nose. Do not swallow.

Pirinase Hayfever Relief quickly starts to reduce inflammation and swelling in your nose, although it may take 3 or 4 days to build up to its maximum protective effect. You should try to use the spray in the morning.

Adults aged 18 years and over:
Spray two puffs into each nostril once daily.

Once your symptoms have improved, you may be able to reduce the dose to one puff into each nostril once daily.

- Do not spray more than 4 sprays (200 micrograms) in a day.
- Use the lowest dose possible to control your symptoms.
- If your symptoms do not improve, or are not well controlled, after 7 days, talk to your doctor or pharmacist.
- Do not use more than the recommended dose.

If you use too many sprays
Tell your doctor.

If you forget to use the spray
Take your next dose at the usual time. Never take two doses together.

Before using a new bottle of Pirinase Hayfever Relief:
- Your Pirinase Hayfever Relief spray has a dust cap which protects the nozzle and keeps it clean. Remember to take it off before you use the spray (Picture 1).
- Before you start to use a new bottle of Pirinase Hayfever Relief, or if you have not used the spray for a few days, press the pump down several times until you get a fine spray.
- Hold the bottle as shown with your forefinger and middle finger on the collar either side of the nozzle and your thumb underneath the bottle.
- Keeping your thumb still, press down with your fingers to pump the spray (Picture 2).
- When doing this make sure you do not point the nozzle at yourself or someone else.
- If the spray still doesn’t work, try to clean it as described under the ‘To clean the spray’ section. Do not try to unblock or enlarge the tiny spray hole with a pin or other sharp objects because this will destroy the spray mechanism.

To Ensure Accurate PDF Viewing and Printing:

FOR SCREEN VIEWING:
Use Adobe Acrobat 5 Professional or Adobe Acrobat Reader, Standard or Professional (higher than 5). Overprint Preview must be activated for accurate on screen viewing.

FOR PRINTING:
Use only Acrobat Professional version 5 or higher. “Apply Overprint Preview” or “Simulate Overprinting” must be activated in the print settings for printing accurate hard copies.
Using Pirinase Hayfever Relief:

1. Shake the bottle well and remove the dust cap.
2. Blow your nose gently.
3. Close one nostril as shown and put the nozzle in the other nostril. Tilt your head forward slightly and keep the bottle upright. Hold the bottle as shown (Picture 3).
4. Start to breathe in slowly through your nose. While you are breathing in, squirt a spray of fine mist into your nostril by pressing down firmly on the collar with your fingers (Picture 6).
5. Breathe out through your mouth. Repeat step 4 to take a second spray in the same nostril.
6. Remove the nozzle from this nostril and breathe out through your mouth (Picture 5).
7. Repeat steps 3 to 6 for the other nostril.
8. After using the spray, wipe the nozzle carefully with a clean tissue or handkerchief and replace the dust cap.

To clean the spray:
1. Take the dust cap and nozzle off (Picture 6).
2. Soak the nozzle and dust cap in warm water for a few minutes and then rinse under a running tap.
3. Shake off the excess water and allow to dry in a warm place — not too hot!
4. Refill the nozzle.
5. If necessary, press the pump down several times until you get a fine spray.

4. Possible side effects

Like all medicines, Pirinase Hayfever Relief can have side effects, but not everybody gets them.

Stop taking the medicine and seek immediate medical help if you experience:
- Allergic reactions. There may include developing a rash, swelling of the mouth or face, or having difficulty breathing.

Stop taking the medicine and tell your doctor if you experience:
- Eye problems such as pain or blurred vision.
- Nasal problems such as pain and/or persistent bleeding.

The following side effects may occur:
- Sneezing after using the spray but this soon stops.
- You may notice an unpleasant taste or smell.
- Nose bleed.
- Dryness or irritation in the nose or throat.

5. How to store Pirinase Hayfever Relief

Keep out of the reach and sight of children.

Do not use this medicine after the “EXP” date shown on the pack.

Use within three months of first use.

Do not store above 30°C.

6. Further information

Active ingredient each spray contains:
- Fluticasone Propionate 50 micrograms.

Other ingredients:
- Dextrose (anhydrous), microcrystalline cellulose, carboxymethylcellulose sodium, phenylethyl alcohol, benzoalkonium chloride, polyethylene 80, purified water and diacetone hydrochloric acid.

The bottle contains 60 sprays.

More about Hayfever

Hayfever is a common allergic condition that affects up to one-in-five people at some point in their life.

What are the symptoms?

Symptoms of hayfever include sneezing, a runny or blocked nose and itchy or watery eyes.

What are the causes?

These are caused when a person has an allergic reaction to pollen. When these tiny particles come into contact with the cells that line your mouth, nose, eyes and throat, they irritate them and trigger an allergic reaction.

What is the pollen count?

The pollen count is affected by the weather and is a measure of how much pollen is in the air. Less pollen is released on cooler, cloudy days than on hot, sunny days. Hayfever symptoms are likely to be worse if the pollen count is high.

The marketing authorization holder is:
GlaxoSmithKline Consumer Healthcare, Brentford, TW8 9GS, UK, and all enquiries should be sent to this address.

The manufacturer is Glaxo Wellcome SA, 09400 Aranda de Duero, Burgos, Spain.

This leaflet was last revised in October 2012.

This information in this leaflet only applies to Pirinase Hayfever Relief for Adults: 0.05% Nasal Spray.

Pirinase and the Pirinase logo are trade marks of the GlaxoSmithKline group of companies.

GlaxoSmithKline

DEVCOMP-0021414

To clean the spray:
1. Take the dust cap and nozzle off (Picture 6).
2. Soak the nozzle and dust cap in warm water for a few minutes and then rinse under a running tap.
3. Shake off the excess water and allow to dry in a warm place — not too hot!
4. Refill the nozzle.
5. If necessary, press the pump down several times until you get a fine spray.

4. Possible side effects

Like all medicines, Pirinase Hayfever Relief can have side effects, but not everybody gets them.

Stop taking the medicine and seek immediate medical help if you experience:
- Allergic reactions. There may include developing a rash, swelling of the mouth or face, or having difficulty breathing.

Stop taking the medicine and tell your doctor if you experience:
- Eye problems such as pain or blurred vision.
- Nasal problems such as pain and/or persistent bleeding.

The following side effects may occur:
- Sneezing after using the spray but this soon stops.
- You may notice an unpleasant taste or smell.
- Nose bleed.
- Dryness or irritation in the nose or throat.

5. How to store Pirinase Hayfever Relief

Keep out of the reach and sight of children.

Do not use this medicine after the “EXP” date shown on the pack.

Use within three months of first use.

Do not store above 30°C.

6. Further information

Active ingredient each spray contains:
- Fluticasone Propionate 50 micrograms.

Other ingredients:
- Dextrose (anhydrous), microcrystalline cellulose, carboxymethylcellulose sodium, phenylethyl alcohol, benzalkonium chloride, polyethylene 80, purified water and diacetone hydrochloric acid.

The bottle contains 60 sprays.

More about Hayfever

Hayfever is a common allergic condition that affects up to one-in-five people at some point in their life.

What are the symptoms?

Symptoms of hayfever include sneezing, a runny or blocked nose and itchy or watery eyes.

What are the causes?

These are caused when a person has an allergic reaction to pollen. When these tiny particles come into contact with the cells that line your mouth, nose, eyes and throat, they irritate them and trigger an allergic reaction.

What is the pollen count?

The pollen count is affected by the weather and is a measure of how much pollen is in the air. Less pollen is released on cooler, cloudy days than on hot, sunny days. Hayfever symptoms are likely to be worse if the pollen count is high.

The marketing authorization holder is:
GlaxoSmithKline Consumer Healthcare, Brentford, TW8 9GS, UK, and all enquiries should be sent to this address.

The manufacturer is Glaxo Wellcome SA, 09400 Aranda de Duero, Burgos, Spain.

This leaflet was last revised in October 2012.

This information in this leaflet only applies to Pirinase Hayfever Relief for Adults: 0.05% Nasal Spray.

Pirinase and the Pirinase logo are trade marks of the GlaxoSmithKline group of companies.

GlaxoSmithKline

DEVCOMP-0021414
CONSULTATION LIST: ARM 83

Advertising Standards Authority
Advisory Committee on Misuse of Drugs
Arthritis Care
Association of Anaesthetists of GB and Ireland
Association of British Cardiac Nurses
Association of Pharmaceutical Importers
Association of the British Pharmaceutical Industry
Asthma and Allergy Research
AstraZeneca UK Ltd
Boots Pharmacists Association
British Association for Nursing in Cardiovascular Care
British Association of Dermatologists
British Association of European Pharmaceutical Distributor
British Association of Pharmaceutical Physicians
British Association of Pharmaceutical Wholesalers
British Generic Manufacturers Association
British Heart Foundation
British International Doctors Association
British Medical Association
British Medical Association (Wales)
British Retail Consortium
British Society for Allergy & Clinical Immunology
British Society of Gastroenterology
Central Medical Advisory Committee
Chemist & Druggist
Committee for Practitioners
Community Pharmacy Magazine
Company Chemists Association
Department of Agriculture
Department of Health, Social Services and Public Safety, Northern Ireland
Dispensing Doctors’ Association
Doctor magazine
General Medical Council
General Practitioners Association (NI)
Health Service Commissioner
Imperial Cancer Research Fund
Independent Healthcare Forum
Medical Protection Society Ltd
Medical Women’s Federation
National AIDS Trust
National Back pain Association
National Federation of retail Newsagents
National Pharmaceutical Association
Neurological Alliance
Northern Ireland Consumer Council
Nursing and Midwifery Council
Ophthalmic Group Committee
OTC Bulletin
Paediatric Chief Pharmacists Group
Patients Association
Pharmacy and Medicines Division (Scotland)
PSNC
Royal College of General Practitioners
Royal College of Nursing
Royal College of Pathologists
Royal College of Physicians
Royal College of Physicians (Edinburgh)
Royal College of Physicians and Surgeons of Glasgow
Royal College of Psychiatrists
Royal College of Surgeons (Edinburgh)
Royal College of Surgeons (England)
Royal Pharmaceutical Society
Scottish Executive
Scottish General Practitioners Committee
Scottish Wholesale Druggists Association
Surgical Dressing Manufacturers Association
Terrence Higgins Trust
The Association of Independent Multiple Pharmacies
The Royal College of Radiologists
UK Homeopathic Medical Association
UK Inter-professional Group
UKCPA
WHICH
Women in medicine